[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":473},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,77,112,136,163,195,220,250,278,303,330,356,380,400,427,453],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642733","unmask-unveiling-the-pathobiology-of-metabolic-dysfunction-associated-steatotic-liver-disease-for-the-discovery-of-novel-therapeutics-and-biomarkers-100642733",false,"NCT07652151","UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers","UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers - Study Protocol Version 2.0","UNMASK","Inclusion Criteria:\n\n* Metabolic disarrangements following ATPIII criteria (i.e. comorbidities such as Type 2 diabetes, central obesity, BMI≥\\>25 kg\u002Fm2, hypertension, dyslipidaemia.\n* Written informed consent\n* No dietetical counsellor\u002Fweight loss higher than 10% within the prior 6 months\n* Age over 18 years old\n* Liver stiffness measurement by Fibroscan ≥ 8, CAP ≥ 248 db\u002Fm and MRI PDFF ≥ 5%. ,\n\nExclusion Criteria:\n\n* Significant alcohol intake (≥30 g\u002Fday in men and ≥20 g\u002Fday in women)\n* Other causes of liver disease (evidence of viral or autoimmune hepatitis, HIV, drug-induced fatty liver or other metabolic liver diseases)\n* Use of recreational drugs\n* Decompensated acute or chronic liver disease\n* Cirrhosis or transplant waitlist\n* Pregnancy or parenteral nutrition\n* No nutritional interventions, medications for weight loss or weight loss higher than 5% within the last year\n* Presence of other comorbidities that would impact lifestyle intervention (i. e. prosthesis)\n* Absence of a personal smartphone with a compatible operating system capable of supporting the Amazfit Bip 6 accelerometer app's functionalities: Android 7.0 or iOS 14.0, or later.","ALL","18 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"NA","Overall design: The study will include one intervention based on Mediterranean diet plus structured lifestyle intervention (150 min\u002Fweek of moderate-intensity or 75 min\u002Fweek of high-intensity exercise) for a total of 16 weeks. Following a screening period of up to 12 months, eligible participants will be included in a single cohort.\n\nStudy details include:\n\n* Study duration will be up to 36 months including the screening period.\n* Intervention will be up to 16 weeks.\n* Visit frequency will be every 4 weeks for the interventional period and every 12 weeks during follow-up.",[27],"MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)",[29,30,31,32,33],"Fibrosis","Obesity","Personalised Medicine","Patient Phenotyping","Lifestyle intervention","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":38},"2026-01-20",{"date":42,"type":21},"2027-02",{"name":44,"class":45},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100635932","supplementation-with-salicornia-extract-rich-in-polyphenols-b-salicornia-to-improve-vascular-health-in-patients-with-dyslipidemia-who-are-not-candidates-for-drug-treatment-low-to-moderate-risk-100635932","NCT07559110","Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are Not Candidates for Drug Treatment (Low to Moderate Risk)","Prospective, Randomized, Open-label, Parallel-Group Pilot Study Compared With Usual Medical Practice and Blinded Analysis (PROBE), to Evaluate the Effect and Safety of Administering a Food Supplement Based on Halophyte Plant Extracts in Patients With Newly Diagnosed Dyslipidemia Who do Not Have an Indication for Medical Treatment.","SALICOL","Inclusion Criteria:\n\n* Participants aged 40 to 65\n* Newly diagnosed dyslipidemia (two years) with SCORE ≥1 - \\\u003C5 (LDL 116 - \\\u003C190 mg\u002FdL): Moderate Risk\n* No indication for pharmacological treatment in primary prevention.\n* Possibility of performing analytical controls at the beginning\u002Fend of the study.\n* Willingness and capacity to give informed consent.\n\nExclusion Criteria:\n\n* Participants with vascular risk requiring pharmacological treatment or high\u002Fvery high vascular risk.\n* Participants in secondary prevention.\n* Hyperthyroidism according to the researcher's criteria.\n* Taking vitamin B supplements and\u002For supplements containing polyphenols in the 30 days prior to the screening visit (at the researcher's discretion).\n* Serious illness with a life expectancy of less than three months.\n* Known allergies or intolerance to halophytic plants.\n* Pregnant or breastfeeding women.\n* Presence of active neoplastic disease.\n* Having participated in another clinical trial with medicines in the 30 days prior to the screening visit, or intending to do so during your participation in this study.\n* Regular consumption of halophyte plants.\n* Participants who, in the researcher's opinion, are not able to comply with the study protocol.","40 Years","65 Years",{"count":58,"type":21},250,[24],"The aim of this clinical trial is to evaluate the ability of a dietary supplement based on salicornia extracts and B vitamins (B-Salicornia) to modulate lipid levels in a population with newly diagnosed dyslipidemia who are not eligible for medical treatment.",[62],"Dyslipidemia",[64,65,66],"food supplement","polyphenol","Dyslipidaemia","NOT_YET_RECRUITING","2026-04-23",{"date":70,"type":38},"2026-04-30",{"date":72,"type":21},"2026-05",{"date":74,"type":21},"2027-05",{"name":44,"class":45},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":76},"100636006","a-scalable-trans-diagnostic-intervention-targeting-adolescent-agency-supported-by-conversational-ai-agencia-100636006","NCT07560072","A Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI (AGENCIA)","A Randomized Controlled Trial Protocol of a Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI","AGENCIA","Inclusion Criteria:\n\n* Adolescents aged 12 to 18 years at enrollment.\n* Presence of emotional or behavioral difficulties causing functional interference (e.g., irritability, impulsivity, emotional dysregulation, conflicts at home or school, avoidance).\n* Difficulties compatible with neurodevelopmental profiles, regardless of formal diagnosis.\n* Ability to use digital materials through a personal device and basic reading skills in Spanish.\n* Availability to attend assessments and participate in the intervention and follow-up schedule.\n* Informed consent from caregivers and assent from the adolescent.\n\nExclusion Criteria:\n\n* Acute clinical risk at pre-screening or screening (e.g., imminent self-harm risk, severe agitation, aggression, disorganized behavior, or unsafe behaviors requiring immediate clinical care).\n* Score of \"Severe\" on any of the three HoNOSCA screening items (self-harm, substance-related problems, or bullying\u002Fsocial problems).\n* Uncompensated sensory, motor, or language barriers preventing valid completion of assessments or participation (e.g., severe visual or hearing impairment, significant receptive\u002Fexpressive language difficulties, motor limitations preventing device use).\n* Intellectual disability defined by screening tools: ABAS-II GAC ≤ 70 or Kaufman Brief Intelligence Test Composite Intelligence Quotient ≤ 70.\n* Any condition judged by the clinical team to require immediate alternative care or that would prevent safe participation.","12 Years",{"count":87,"type":21},465,[24],"The aim of this clinical trial is to evaluate whether AGENCIA, a brief psychological program supported by digital technology and artificial intelligence, can help reduce emotional and behavioral difficulties in adolescents aged 12 to 18. These difficulties may include irritability, impulsive behaviors, conflicts at home or at school, or difficulties in managing intense emotions. The study also aims to determine whether the effects are similar across adolescents with different symptom profiles or neurodevelopmental characteristics.\n\nParticipants will be randomly assigned to one of three groups:\n\nAGENCIA Digital: a self-guided online version completed at home. AGENCIA in-person with a digital assistant: a clinician-delivered version supported by an interactive digital assistant to guide the exercises.\n\nDigital psychoeducation (control): a self-guided online program providing general information about adolescent well-being.\n\nThe main research questions are:\n\nDoes AGENCIA reduce overall emotional and behavioral difficulties? Does the program improve functioning, family accommodation, and personal agency (a young person's sense of being able to act and make changes)? Are the effects similar across adolescents with different profiles or neurodevelopmental characteristics?\n\nParticipants will:\n\n* Complete three structured sessions depending on their assigned group.\n* Complete brief online questionnaires at baseline (T0), immediately after the sessions (T1), and at 1-month (T2) and 6-month (T3) follow-ups.\n* Receive brief phone calls during follow-ups to support questionnaire completion.\n\nA total of 465 adolescents will take part in the study. Participation is voluntary and does not replace usual clinical care. The study does not involve medication or invasive procedures, and all digital tools operate within secure institutional systems.",[91,92,93,94,95,96],"Irritability","Neurodevelopmental Disorders","Impulsivity","Emotional Dysregulation","Distress, Emotional","Distress, Psychological",[98,99,100,101,102,103,104,105],"Adolescents","Randomized controlled trial","Personal Agency","Digital health intervention","Neurodevelopmental disorders","Family accommodation","Conversational AI","Trans diagnostic interventions",{"date":70,"type":38},{"date":108,"type":21},"2026-04-01",{"date":110,"type":21},"2028-12-31",{"name":44,"class":45},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":76},"100633075","out-patiente-management-for-gangrenous-acute-appendicitis-the-pendi-csi-ii-randomized-clinical-trial-100633075","NCT07521969","Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial.","Safety, Efficacy, and Cost-effectiveness of Outpatient Surgery for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial.","PENDI-CSI II","Inclusion Criteria:\n\n* Acute gangrenous appendicitis confirmed during surgery.\n* Patient who meets the criteria to be discharged on an outpatient basis\n* Signature of informed consent.\n* Older than 14 years of age\n\nExclusion Criteria:\n\n* \\- Uncomplicated appendectomy.\n* Intra-operative purulent or faecaloid peritonitis\n* Appendicular abscess or plastron diagnosed by imaging.\n* Paralytic ileus preventing oral tolerance.\n* Need for placement of abdominal drainage.\n* ASA IV and some selected ASA III.\n* Immunosuppression.\n* Patients with active neoplasia.\n* Pregnancy.\n* Doubts in the definitive diagnosis.\n* Suspicion of inflammatory bowel disease.\n* No family support.\n* Failure to sign the informed consent form.\n* Impossibility to comply with the follow-up.","14 Years",{"count":122,"type":21},122,[24],"PHASE II-III CLINICAL TRIAL TO EVALUATE THE SAFETY, EFFECTIVENESS AND EFFICIENCY OF DISCHARGE TO OUTPATIENT SURGERY IN PATIENTS WITH ACUTE GANGRENOUS APPENDICITIS UNDERGOING EMERGENCY SURGERY.",[126,127],"Appendicitis Acute","Gangrenous Appendicitis","2026-04-16",{"date":130,"type":38},"2026-04-21",{"date":132,"type":38},"2025-11-01",{"date":134,"type":21},"2027-11-01",{"name":44,"class":45},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100623433","predictive-score-in-patients-with-hematological-malignancies-colonized-by-multidrug-resistant-enterobacteriaceae-100623433","NCT07396571","Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","Development of a Predictive Infection Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","SCREEN-IN","Inclusion criteria\n\n* Patients admitted to Hematology departments with hematological diseases, including: myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, chronic myeloproliferative leukemias, lymphomas, or other hematological disorders.\n* Patients scheduled to receive treatment for their underlying hematological disease, including myeloablative\u002Fcytotoxic chemotherapy, conditioning chemotherapy for hematopoietic stem cell transplantation (autologous, allogeneic, or other types), lymphodepleting chemotherapy for CAR-T cell therapy, and\u002For other treatments expected to induce neutropenia.\n* Patients expected to develop neutropenia (neutrophil count \\\u003C 0.5 \\\\times 10\\^9\u002FL, or \\\u003C 1.0 \\\\times 10\\^9\u002FL when predicted to fall below 0.5 \\\\times 10\\^9\u002FL within the next 48 hours) in the coming days.\n* Those who have signed the informed consent form.\n* Participation in another study is permitted, provided it is observational and does not influence the potential colonization status.\n\nExclusion criteria\n\n* Psychiatric disorder or inability to understand or follow the protocol instructions.\n* Terminally ill patients or those with an estimated life expectancy of less than 30 days.\n* Previous enrollment in the study.\n* Known prior colonization by ESBL-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE).\n* Physician's discretion: The patient's attending physician prefers not to include the patient in the study.",{"count":145,"type":21},535,"OBSERVATIONAL","The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to develop and validate a predictive model of infection caused by ESBL-producing Enterobacterales and CPE in patients previously colonized by the same bacteria.\n\nThe main questions the study aims to answer are:\n\n* What are the risk factors for ESBL-producing Enterobacterales and CPE colonization in patients with severe neutropenia?\n* Can a predictive model be developed to accurately predict infections in the colonized patients?\n\nStudy Design \\& Participants: Participants will be screened after receiving neutropenia-inducing treatment (e.g., chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy, or others). A baseline rectal swab will be collected to assess initial colonization status, followed by weekly swabs throughout the duration of neutropenia. Patients will be followed for 90 days from initial screening, during which the study team will record any infections, with an additional 30-day follow-up period. All hospitalization data will be recorded.",[149,150,151,152,153],"Hemato-oncologic Patients","Colonization","Neutropenia","Enterobacteria Non Susceptible to Carbapenem Carrier","ESBL-producing Enterobacteriaceae Infections","2026-02-27",{"date":156,"type":38},"2026-03-02",{"date":158,"type":21},"2026-02",{"date":160,"type":21},"2028-12",{"name":44,"class":45},15,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100622521","phase-2-adjuvant-clopidogrel-in-staphylococcus-aureus-bacteremia-100622521","NCT07384702","Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia","Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)","CLOPI-SNAP","Inclusion Criteria:\n\nTo be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:\n\n* Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.\n* Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.\n* Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.\n\nExclusion Criteria:\n\nGeneral Medical and Safety Factors:\n\n* Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).\n* Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).\n* Pregnancy: Pregnant or breastfeeding women.\n\nHigh Risk of Bleeding or Hematologic Disorders:\n\n* Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.\n* Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.\n* Coagulation parameters: Platelet count \\\u003C50,000\u002Fmm³ or known coagulation disorders.\n* Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted).\n\nSpecific Diagnoses and Clinical Criteria:\n\n* Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections.\n* Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.",true,{"count":173,"type":21},230,[175],"PHASE2","The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).",[178],"Bacteremia Due to Staphylococcus Aureus",[180,181,182,183,184,185],"bacteriemia","Staphylococcus aureus","adjunctive treatment","Platform trial","Clopidogrel","Desirability of Outcome Ranking","2026-02-03",{"date":188,"type":38},"2026-02-05",{"date":190,"type":21},"2026-06",{"date":192,"type":21},"2030-06",{"name":44,"class":45},20,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":76},"100620115","a-multicenter-randomized-clinical-trial-compared-with-standard-clinical-practice-to-evaluate-the-efficacy-of-a-polyphenol-rich-salicornia-extract-in-the-progression-of-cognitive-decline-in-a-cohort-of-patients-with-lacunar-infarcts-salacunar-100620115","NCT07353424","A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts (SALACUNAR)","A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts","SALACUNAR","Inclusion Criteria:\n\n\\- Patients with lacunar ischemic stroke, confirmed by cranial magnetic resonance imaging performed within the year prior to inclusion, who have an mRS of 3 or less at the time of inclusion will be included (independent patients or those who require assistance with walking). The inclusion age will be between 40 and 90 years.\n\nExclusion Criteria:\n\n* Consumption of vitamin supplements or polyphenol supplements within 30 days prior to inclusion\n* Hyperthyroidism\n* mRS \\>3, serious illness, or expected life expectancy \\\u003C12 months\n* Dysphagia preventing intake of the study capsules\n* Allergies or intolerance to halophytes\n* Pregnant or breastfeeding\n* Active neoplasia\n* Participation in another study","90 Years",{"count":205,"type":21},300,[24],"SALACUNAR (LACI-2-polyphenols) is a multi-center randomized controlled trial (RCT) to evaluate the effect of a polyphenol-rich supplement on small vessel neurovascular disease. Specifically, the compound to be tested is a dietary supplement based on Salicornia extract and B vitamins (B-salicornia), which in previous studies has demonstrated a good safety profile and consistent effects in reducing homocysteine levels and improving cognitive outcomes (MOCA) in patients with lacunar infarcts. This has been used to calculate the sample size based on these endpoints. Considering an intragroup variability of the treatment groups (sigma) of 6.07, and accepting an alpha risk of 0.05, a sample of 150 patients per group would achieve a 1-beta statistical power greater than 0.8 in a two-tailed test for differences between means of at least two points on the MOCA scale.\n\nThree hundred patients with lacunar infarcts diagnosed within the last year and confirmed by MRI performed as part of routine clinical practice will be included.\n\nWe will administer 500 mg\u002F24 h of the dietary supplement B-Salicornia for six months (or the control group will be managed according to routine clinical practice) following a PROBE design.\n\nRoutine blood tests will be performed pre- and post-treatment, with routine vascular parameters such as lipids and homocysteine, as well as baseline and six-month assessments of neuropsychological and gait scales.",[209],"Lacunar Stroke",[211,64,212],"attack","cognition","2026-01-19",{"date":40,"type":38},{"date":216,"type":38},"2025-06-01",{"date":218,"type":21},"2026-12-31",{"name":44,"class":45},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100604737","phase-3-comparison-of-esketamine-nasal-spray-vsaripiprazole-in-treatresistant-major-depressive-disorder-in-elderly-patients-100604737","NCT07153406","Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","Comparison of Esketamine Versus Aripiprazole,Both in Combination With a SSRI\u002FSNRI(Selective Serotonin Reuptake Inhibitors\u002FSerotonin and Norepinephrine Reuptake Inhibitors )in Treatment-resistant Major Depressive Disorder in Elderly Patients","CESAR","Inclusion Criteria:\n\n* Patients between 60-74 years\n* To be receiving antidepressant treatment that includes an antidepressant at the time of screening that is not responding (less than 25% improvement in symptoms) after receiving an adequate dose \\[or local equivalent, if applicable\\] for at least 6 weeks and have been increased to the dose maximum allowed\n* Current antidepressant treatment must have been immediately preceded by failure to respond to at least 3, but not more than 5, different consecutive treatments (all within the same moderately severe depressive episode) with antidepressant drugs (AD) taken at an appropriate dose for at least least 6 weeks (3 antidepressant failures including the current one)\n* To have been treated with at least 3 different classes of antidepressants between treatments taken at appropriate doses for at least 6 weeks without response in the current moderate to severe depressive episode (including current treatment with an antidepressant)\n* To be taking a single oral antidepressant on day 1 before randomization\n* Participants who, at the time of screening, are taking a combination of antidepressants and\u002For rescue treatment (other than aripiprazole) for the current moderate to severe depressive episode may participate in the study.\n\nExclusion Criteria:\n\n* Treatment with drugs contraindicated with the use of esketamine and aripiprazole.\n* Patients in whom a high risk of suicide is detected at the screening visit, according to the criteria established by Columbia University according to the C-SSRS evaluation\n* Patients who are participating in another clinical trial with active treatment\n* Patients who do not have the capacity to consent to participation in the trial or who do not have a representative to confirm their participation\n* Hypersensitivity to any of the active ingredients of any of the branches of treatment, or to any of the excipients of its pharmaceutical form\n* Patients in whom increased blood pressure or blood pressure intracranial fluid poses a serious risk","60 Years","74 Years",{"count":231,"type":21},220,[233],"PHASE3","Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (\\>60 years) who suffer from treatment-resistant major depressive",[236],"Depressive Disorder",[236,238,239,240],"Moderate-severe depressive episode.","Antidepressants","Psychotropics","2025-08-29",{"date":243,"type":38},"2025-09-04",{"date":245,"type":21},"2025-09-15",{"date":247,"type":21},"2029-01-15",{"name":44,"class":45},9,{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":277},"100548661","phase-4-ampicillin-and-ceftriaxone-for-the-treatment-of-enterococcus-faecalis-infective-endocarditis-100548661","NCT06423898","Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","Efficacy and Safety of Ampicillin and Ceftriaxone Continuous Infusion Versus Standard Therapy for the Treatment of Enterococcus Faecalis Infective Endocarditis (DOβLEI Study)","DOBLEI","Inclusion Criteria:\n\n* Adult patients\n* Possible or definitive diagnosis of infective endocarditis due to Enterococcus faecalis\n* Signed informed consent of patients\n\nExclusion Criteria:\n\n* Allergy to penicillins or cephalosporins\n* Pregnancy and lactation\n* Polymicrobial infection including microorganisms different to E. faecalis",{"count":259,"type":21},284,[261],"PHASE4","Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the standard treatment, usually administered in hospitalized patients.",[264],"Endocarditis, Infective",[264,266,267,268,269],"Enterococcus faecalis","Antibiotics","Outpatient Infusion Therapies","Outpatient Care","2025-07-24",{"date":272,"type":38},"2025-07-25",{"date":274,"type":38},"2024-10-09",{"date":110,"type":21},{"name":44,"class":45},18,{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":46},"100399249","phase-2-trial-of-the-combined-use-of-thiamine-and-biotin-in-patients-with-huntingtons-disease-100399249","NCT04478734","Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease","Multicentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s Disease","HUNTIAM","Inclusion Criteria:\n\n* Patients of legal age with manifest Huntington's disease with motor symptoms (chorea, dystonia or bradykinesia) and\u002For neuropsychiatric; and genetic confirmation of a number of repetitions of the cytosine-adenine-guanine trinucleotide (CAG triplet) in the HTT gene (coding for HTT) greater than or equal to 39\n* Patients should be capable of giving informed consent and attending the planned visit of the study.\n* Women of childbearing age should obtain a negative result in the serum or urine pregnancy test at the screening visit. They must also accept the use of appropriate contraceptive methods during the course of the clinical trial and men who have a partner of childbearing age, accept the use of contraceptive methods\n\nExclusion Criteria:\n\n* Medical comorbidities considered clinically significant by the clinical judgment of the investigators.\n* Pregnancy or lactation\n* Patients with HD dependents on the basic routine daily life activities (UHDRS TFC \\\u003C 7) or a severe cognitive decline.\n* Active psychosis at the moment of the screening evaluation.\n* Severe renal failure.\n* Patients previously treated with thiamine and\u002For biotin or enrolled in other HD clinical trial with oligonucleotide antisense (IONIS-HTTRX (RG6042).",{"count":287,"type":21},24,[175],"Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year.\n\nOur main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients",[291],"Huntington Disease",[293,294],"thiamine and biotine","combination therapy","2025-02-24",{"date":297,"type":38},"2025-02-25",{"date":299,"type":38},"2023-04-12",{"date":301,"type":21},"2025-12-30",{"name":44,"class":45},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":76},"100570387","clinical-and-ecological-impact-of-a-primary-care-antimicrobial-stewardship-program-based-on-telematic-educational-interviews-telmaco-trial-100570387","NCT06706583","Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial)","Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews. A Cluster Randomized Clinical Trial (TELÉMACO Trial)","TELÉMACO","Inclusion criteria:\n\na) Primary Care centres within the reference area of the University Hospital Virgen del Rocío.\n\nExclusion criteria:\n\n1. Emergency departments.\n2. Odontology offices.\n3. DDD per Health centre less than 5.78",{"count":312,"type":21},30,[24],"Brief Summary: Open-label, cluster randomized, multicenter clinical trial to evaluate the clinical and ecological impact of a Primary Care ASP based on telematic educational interviews.",[316],"Community Acquired Infections",[318,319,320,321],"Antimicrobial Stewardship Program (ASP)","Primary Care","Telemedicine","PIRASOA","2024-11-22",{"date":324,"type":38},"2024-11-26",{"date":326,"type":21},"2024-12-01",{"date":328,"type":21},"2026-03-31",{"name":44,"class":45},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":338,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100562373","phase-2-tmlifludarabinemelphalan-conditioning-for-allogeneic-transplantation-in-high-risk-myelodysplastic-syndrome-or-acute-myeloid-leukemia-100562373","NCT06602323","TMLI\u002FFludarabine\u002FMelphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Administered in Combination With a Reduced-intensity Regimen Based on Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) in Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","TMLI-RI","Inclusion Criteria:\n\n* The participant has the ability and willingness to sign the informed consent document. (For adults, only participants with mild cognitive abilities may use a legally authorized representative).\n* Documented (signed) informed consent. The patient, family member, and doctor of the transplant staff (doctor, nurse, and social worker) meet at least once before the transplant procedure begins. During this meeting, all relevant information regarding the risks and benefits to the donor and recipient will be presented. Alternative treatment modalities will be discussed. The risks are explained in detail in the attached consent forms.\n* Age: ≥ 50 years or Haematopoietic Cell Transplantation-Comorbidity Index pre-transplant score ≥ 3 or any other condition that precludes the use of a fully myeloablative conditioning regimen.\n* Karnofsky's performance status ≥ 70%.\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukemia or acute myeloid leukemia with relapsed\u002Frefractory active disease (i.e. ≥5% bone marrow blasts), or in complete remission or morphologic leukemia-free state with evidence of measurable residual disease as assessed by multiparameter flow cytometry (≥ 0,1%) or next-generation sequencing (in the case of fms-like tyrosine kinase-3 internal tandem duplication-mutated AML).\n* All candidates for this study must have an 8\u002F8 human leukocyte antigens-identical (A, B, C, DR) sibling donor or an unrelated donor with at least 8\u002F8 human leukocyte antigens matching. A single allele mismatch in A, B, C, DR or dq and a kir mismatch in C shall be allowed. All combinations of donor\u002Frecipient \"abo\" blood types are acceptable; as even major \"abo\" compatibilities can be treated using a variety of techniques (red blood cell exchange or plasma exchange).\n* The time elapsed since the end of the last induction or re-induction cycle must be greater than or equal to 14 days.\n* Total bilirubin ≤ 1.5 mg\u002FdL x Upper Limit of Normality OR 3 x upper limit of normal for Gilbert's disease.\n* Serum glutamate oxaloacetate transaminase \\& serum glutamate pyruvate transaminase ≤ 5 x Upper Limit of Normality.\n* Serum creatinine ≤ 1.3 mg\u002FdL or creatinine clearance measured ≥ 80 mL\u002Fmin for 24 hours of urine collection.\n* Women of childbearing age only: Negative urine or serum pregnancy test.\n* Men AND women of childbearing potential agree to use appropriate contraceptives (hormonal or barrier contraception or abstinence) prior to study entry and for six months following the duration of study participation. If a woman becomes pregnant or suspects she is pregnant while participating in the trial, she should inform her treating physician immediately.\n* Pulmonary function tests: forced expiratory volume in one second (FEV1) and Carbon Monoxide Diffusion Capacity (DLCO) (adjusted for Hb) ≥ 50% from expected normal value.\n* Patients should undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or clinically relevant arrhythmia, and a ≥50% ejection fraction established by multigated acquisition scan or echocardiogram.\n* ECG showing no ischemic changes or clinically significant arrhythmia.\n* The time elapsed since the end of the last induction or reinduction cycle must be greater than or equal to 14 days.\n\nExclusion Criteria:\n\n* Patients who have received a previous autologous (within the last year) or allogeneic transplant (at any time) are excluded.\n* Previous radiation therapy which would preclude the use of TMLI.\n* Plans during the trial to receive any other investigational (non-trial-related) agents.\n* Uncontrolled disease, including ongoing or active infection.\n* History of allergic reactions attributed to compounds of chemical or biological composition similar to cyclophosphamide or etoposide.\n* Patients with other active malignancies are not eligible for this study, other than the malignancies discussed.\n* Patients with a psychological or medical condition that the patient's physician deems unacceptable to proceed with allogeneic hematopoietic stem cell transplantation.\n* Women who plan to become pregnant or breastfeed during the trial.\n* Patients who do not agree to practice effective forms of contraception.\n* Subjects who, in the opinion of the investigator, may not be able to meet the safety control requirements of the study.","50 Years","99 Years",{"count":341,"type":21},34,[175],"The goal of this clinical trial is to learn if drugs (fludarabine and melphalan) combinated with a targeted irradiation (in bone marrow and in lymphoid tissue) works to treat blood cancers (high risk myelodysplastic syndrome or acute myeloid leukemia) in adults. It will also learn about the safety of this combination of drugs and irradiation. The main questions it aims to answer are:\n\n* Does this combined therapy result in an improved survival and decreased relapse\u002Fprogression rate after a bone marrow transplant?\n* What toxicities or complications do participants have when taking this combined therapy?\n\nResearchers will use this combined therapy to see if it works to treat high risk myelodysplastic syndrome or acute myeloid leukemia through the evaluation of the length of time (during the treatment and 2 years after the treatment) that a patient lives with the disease but it does not get worse (progression-free survival).\n\nParticipants will:\n\n* Receive the combined therapy (study treatment) one week before the bone marrow transplant.\n* Receive too post-transplant medication as per usual clinical practice.\n\nPatients will have to attend medical visits (checkups and tests) for 2 years.",[345,346],"Myelodysplastic Syndromes","Acute Myeloid Leukemia",[345,346],"2024-09-16",{"date":350,"type":38},"2024-09-19",{"date":352,"type":21},"2024-10-01",{"date":354,"type":21},"2028-10-01",{"name":44,"class":45},{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":338,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":76},"100562115","phase-2-tmli-plus-chemotherapy-in-high-risk-myelodysplastic-syndrome-or-acute-myeloid-leukemia-100562115","NCT06598969","TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia","Phase II Study of TMLI Administered in Combination With a Myeloablative Regimen (Cyclophosphamide + Etoposide) for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia","TMLI-MA","Inclusion Criteria:\n\n* The participant has the ability and willingness to sign the informed consent document\n* Age ≥18 to ≤50 years.\n* Karnofsky's performance status should be ≥70%.\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukemia or acute myeloid leukemia with relapsed\u002Frefractory active disease, or in complete remission or morphologic leukemia-free state with evidence of measurable residual disease as assessed by multiparameter flow cytometry (≥ 0,1%) or next-generation sequencing\n* All candidates for this study must have an Human leukocyte antigens (A, B, C, DR) identical siblings who are willing to donate bone marrow or peripheral blood hematopoietic progenitors or an 8\u002F8 matched unrelated donor. A single allele mismatch in A, B, C or DR beta chain 1 shall be allowed\n* Total bilirubin ≤ 1.5 x upper limit of normal or 3 x upper limit of normal for Gilbert's disease.\n* serum glutamate oxaloacetate transaminase \\& serum glutamate pyruvate transaminaseT ≤ 5 x upper limit of normal.\n* Serum creatinine ≤ 1.3 mg\u002FdL or creatinine clearance measured ≥ 80 mL\u002Fmin for 24 hours of urine collection\n* Women of childbearing age only: Negative urine or serum pregnancy test\n* Pulmonary function tests: forced expiratory volume in one second and Carbon Monoxide Diffusion Capacity (adjusted for Hb) ≥ 50% from expected normal value\n* Patients should undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or clinically relevant arrhythmia, and a ≥50% ejection fraction established by Multi-Gated Acquisition Scan or echocardiogram\n* Men and women of childbearing potential agree to use appropriate contraceptives (hormonal or barrier contraception or abstinence) prior to study entry and for six months following the duration of study participation\n* The time elapsed since the end of the last induction or reinduction cycle must be greater than or equal to 14 days\n\nExclusion Criteria:\n\n* Patients who have received a previous autologous (within the last year) or allogeneic transplant (at any time) are excluded\n* Previous radiation therapy, which would preclude the use of total bone marrow and lymphoid irradiation\n* Plans during the trial to receive any other investigational (non-trial-related) agents\n* Uncontrolled disease, including ongoing or active infection\n* History of allergic reactions attributed to compounds of chemical or biological composition similar to cyclophosphamide or etoposide\n* Patients with other active malignancies are not eligible for this study, other than the malignancies discussed\n* Patients with a psychological or medical condition that the patient's physician deems unacceptable to proceed with allogeneic hematopoietic stem cell transplantation\n* Women who plan to become pregnant or breastfeed during the trial\n* Patients who do not agree to practice effective forms of contraception\n* Subjects who, in the opinion of the investigator, may not be able to meet the safety control requirements of the study",{"count":365,"type":21},58,[175],"Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety\u002Ftolerability of TMLI\u002Fcyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.",[345,369],"Myeloid Leukemia, Acute",[371,372,373],"High-Risk myelodysplastic syndrome","Acute myeloid leukemia","Total narrow and lymphoid irradiation",{"date":350,"type":38},{"date":376,"type":21},"2024-12-30",{"date":378,"type":21},"2028-12-30",{"name":44,"class":45},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":76},"100560227","identification-and-validation-of-clinical-phenotypes-in-staphylococcus-aureus-bacteremia-and-their-association-with-mortality-and-development-of-complicated-bacteremia-100560227","NCT06574399","Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia","FEN-AUREUS","FOR STANDARD STUDY:\n\nInclusion Criteria:\n\n* Adults and children with clinically significant Staphylococcus aureus bacteremia (at least two classic systemic inflammatory response criteria: fever, tachycardia, tachypnea, lowered awareness, low blood pressure, leucocytosis\u002Fleucopenia, organ failure)\n\nExclusion Criteria:\n\n* Patients with non-clinically significant bacteremia.\n* Death within 48 hours after detection of bacteremia for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases.\n* Patients under palliative sedation at the time of bacteremia report.\n* Polymicrobial bacteremia.\n\nFOR EXTENDED STUDY:\n\nInclusion Criteria:\n\n* Adults with clinically significant Staphylococcus aureus bacteremia included in the Standard Study\n* Selected at random as one of the model phenotypes until completing recruitment (only HUVM and HUVV)\n\nExclusion Criteria:\n\n* Patients with non-clinically significant bacteremia.\n* Death within 48 hours after detection of bacteremia for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases, life expectancy less than 48 hours for the inclusion of retrospective cases.\n* Patients under palliative sedation at the time of bacteremia report.\n* Polymicrobial bacteremia.",{"count":388,"type":21},1000,"The goal of this observational study is to determine retrospectively whether different patient clinical phenotypes (adults and children) develop Staphylococcus aureus bacteremia.The main questions it aims to answer qre:\n\n1. Evaluate its reproducibility and correlation with mortality\n2. Derive and validate a simplified probabilistic model for phenotype assignment\n3. External validation of the simplified probabilistic phenotype assignment model found and its association with mortality and development of complicated bacteremia in a prospective cohort\n4. Apply microbiological, biochemical and immunological techniques to explain the physiopathological and genetic mechanisms underlying the phenotypes.",[391],"Staphylococcus Aureus Bacteremia","2024-08-26",{"date":394,"type":38},"2024-08-27",{"date":396,"type":38},"2023-05-01",{"date":398,"type":21},"2025-03-31",{"name":44,"class":45},{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":426},"100514728","phase-1-trial-of-an-investigational-drug-after-rejecting-the-relapse-of-an-allogeneic-transplant-100514728","NCT05982275","Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant","Anti-BCMA Chimeric Antigen Receptor (CARTemis-1) T-lymphocyte Therapy in the Treatment of Patients With Multiple Myeloma in Relapse After Allogeneic Transplant: Endothelial Growth Factor Receptor Expression as a Control Mechanism of Treatment-derived Complications","CARTemis-1","Inclusion Criteria:\n\n1. Patients \\> 18 years old with a diagnosis of post-allogeneic transplant relapse multiple myeloma.\n2. Measurable disease at the time of screening\n3. Previous treatment with ≥2 lines before and\u002For after allogeneic transplant.\n4. Patients who are not receiving immunosuppressants at least 1 month before inclusion and who do not have active graft-versus-host disease.\n5. Eastern Cooperative Oncology Group functional status from 0 to 1.\n6. Life expectancy greater than 3 months (at the time of screening)\n7. Patients who give their consent by signing the Informed Consent document.\n\nExclusion Criteria:\n\n1. Active systemic immunosuppressive treatment\n2. Patients who have previously received treatment with CAR-T Anti-BCMA.\n3. Absolute lymphocyte count \\\u003C0.2x109\u002FL\n4. Previous neoplasm, except if it has been in complete remission \\>3 years, with the exception of skin carcinoma (non-melanoma)\n5. Active infection requiring treatment.\n6. Active HIV, hepatitis B virus or hepatitis C virus infection.\n7. Uncontrolled medical illness.\n8. Severe organic disease that meets any of the following criteria: left ventricular ejection fraction \\\u003C40%, carbon monoxide diffusion test \\\u003C40%, glomerular filtration rate \\\u003C50 ml\u002Fmin, bilirubin \\>3 normal value (except Gilbert syndrome).\n9. Previous diagnosis of symptomatic amyloid light chain or primary amyloidosis or POEMS Syndrome.\n10. Pregnant or lactating women.\n11. Women of childbearing age, unable or unwilling to use highly effective contraceptive methods.\n12. Men who cannot or do not wish to use highly effective contraceptive methods. The partner of the male participants, if they are women of childbearing age, must also use highly effective contraceptive methods during the study period.\n13. Contraindication to receive lymphodepleting chemotherapy.\n14. Patients with known hypersensitivity to the active ingredients or any of the excipients of the product to be infused.",{"count":409,"type":21},25,[411,175],"PHASE1","Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells. To overcome some of the potential limitations of this therapy, a new and optimized Anti-BCMA CAR-T has been developed, with the aim of using it in patients with MM who relapse after Allogeneic Haematopoietic Haematopoietic Progenitor. This trial is a prospective phase I\u002FII trial with a 3+3 design. Once Dose Limiting Toxicity is identified, Phase II will begin to assess the efficacy of the procedure.",[414,415],"Multiple Myeloma","Allogeneic Stem Cell Transplantation",[417,418],"Chimeric antigen receptor-T cell therapy","B-Cell Maturation Antigen","2024-05-13",{"date":421,"type":38},"2024-05-14",{"date":376,"type":21},{"date":424,"type":21},"2029-12-31",{"name":44,"class":45},5,{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":76},"100370308","accelerated-partial-irradiation-of-the-breast-new-altered-fractionation-100370308","NCT04101656","Accelerated Partial Irradiation of the Breast: New Altered Fractionation","Inclusion Criteria:\n\n* ≥ 45 years or 40-44 if there isn´t any other risk factor\n* Diagnosed with infiltrating ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS) and that have undergone conservative surgery without ganglionar involvement (pN0) of any histological degree except from invasive lobular carcinoma and with a size ≤ 3 cm.\n* Disease free margins (R0: \\> 2mm).\n* Positive and negative estrogen receptor tumors.\n\nExclusion Criteria:\n\n* Multicentric and multifocal tumors, except from if it´s focal and the only risk factor.\n* Patients must not have undergone a neoadjuvant QT therapy.\n* Patients with BRCA positive mutation will be excluded.\n* Those patients unable or unsuitable to understand and accept the informed consent.\n* Metastasic´s affectation evidence.\n* Extensive lymphovascular invasion, except from if the total resulting size of the focus and breast parenchyma addition is ≤ 3cm.\n* Breast implants presence in the breast that´s going to be treated.\n* Contraindicated radiotherapy treatment due to a diagnosis of cutaneous lupus, pregnancy or scleroderma.\n* Inability to fully know the dosimetric data of the APBI plan.",{"count":434,"type":21},174,"The aim of this observational study is to evaluate a dose fractionation scheme for APBI using external radiotherapy with modulated intensity technique (IMRT), with the possible impact on the quality of life of patients as it decreases the treatment number of sessions and improves the efficiency and accessibility.",[437],"Breast Cancer",[437,439,440,441,442,443,444],"Radiotherapy","Accelerated Partial Breast Irradiation","APBI","Modulated Intensity Radiotherapy","IMRT","Positive estrogen receptor","2023-11-07",{"date":447,"type":38},"2023-11-08",{"date":449,"type":38},"2019-10-15",{"date":451,"type":21},"2026-06-15",{"name":44,"class":45},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":472,"locationsCount":76},"100444053","persistence-of-biological-treatment-and-inhibitors-of-jak-kinases-in-patients-with-rheumatoid-arthritis-100444053","NCT05062421","Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.","Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.","Arthritis","Inclusion Criteria:\n\n* Patients aged ≥18 years.\n* With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR \u002F EULAR criteria.\n* Who have received at least one of the doses of the study drugs.\n* In follow-up in the consultations of the UGC of Rheumatology of the HUVM.\n* With at least two complete evaluations (baseline and final) of clinical variables.\n\nExclusion Criteria:\n\n* Patients where the medical records lack sufficient baseline and final variables to perform the analysis.\n* Patients in whom more than 50% of the variables to be collected are missing in the data collection.",{"count":462,"type":21},540,"One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).\n\nThese patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.",[465],"Arthritis, Rheumatoid","2021-11-15",{"date":468,"type":38},"2021-11-17",{"date":470,"type":38},"2021-04-01",{"date":218,"type":21},{"name":44,"class":45},""]